Metavia (MTVA) closed at $1.01 on November 20, 2026, down 5.6% from the previous close, on volume of 35,718 shares (30-day average 144,594).
Data as of November 20, 2026.
MetaVia Receives Nasdaq Compliance Notice Over Equity Deficiency
TipRanks (Wed, 18-Nov 9:29 AM ET)
Analysts Are Bullish on These Healthcare Stocks: MetaVia (MTVA), Immunic (IMUX)
TipRanks (Wed, 18-Nov 4:40 AM ET)
Analysts Offer Insights on Healthcare Companies: MetaVia (MTVA) and Sanofi (OtherSNYNF)
TipRanks (Tue, 17-Nov 2:50 PM ET)
MetaVia Completes DA-1726 Phase 1 Trial, Extends Treatment
TipRanks (Tue, 17-Nov 9:29 AM ET)
PRNewswire (Tue, 17-Nov 8:31 AM ET)
PRNewswire (Mon, 16-Nov 8:31 AM ET)
MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update
PRNewswire (Fri, 13-Nov 8:31 AM ET)
PRNewswire (Thu, 12-Nov 8:31 AM ET)
MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek 2026
PRNewswire (Mon, 9-Nov 8:31 AM ET)
PRNewswire (Thu, 5-Nov 8:55 AM ET)
MetaVia Inc is a clinical-stage biotechnology company focused on developing treatments for liver-related cardiometabolic diseases. Its product pipeline includes DA-1726, an oxyntomodulin analogue that acts as a dual GLP-1 and glucagon receptor agonist, being developed for metabolic and alcohol-associated liver diseases. The company is also developing vanoglipel (DA-1241), a GPR119 agonist, in combination with resmetirom for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Metavia trades on the NASDAQ stock market under the symbol MTVA.
As of November 20, 2026, MTVA stock price declined to $1.01 with 35,718 million shares trading.
MTVA has a beta of 1.97, meaning it tends to be more sensitive to market movements. MTVA has a correlation of 0.03 to the broad based SPY ETF.
MTVA has a market cap of $6.81 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that MTVA belongs to (by Net Assets): VXF.
MTVA has underperformed the market in the last year with a price return of -86.2% while the SPY ETF gained +6.9%. MTVA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -29.9% and -29.4%, respectively, while the SPY returned -9.3% and -6.2%, respectively.
MTVA support price is $.95 and resistance is $1.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MTVA shares will trade within this expected range on the day.